Skip to main content
. Author manuscript; available in PMC: 2024 May 10.
Published in final edited form as: ACS Appl Mater Interfaces. 2023 Apr 28;15(18):21877–21892. doi: 10.1021/acsami.3c01501

Figure 5.

Figure 5.

Top LNP (B6) delivers functional K27 DARPin in vitro. (A) TEM image of top LNP formulation, B6, showing multilamellar structure. Image supports DLS-determined size of 198.4 ± 4.4 nm. (B) Delivery efficiency, as measured by %GFP+ cells, and toxicity, represented as % viability. Delivery efficiency plateaus around 90% above 100 nM. (C, D) D30 modification of K27 allows for LNP stability out to at least 45 days post formulation. K27 without D30 modification shows increase in size and decrease in delivery efficacy after being stored. ***: p<0.001. (E) Western blot shows decrease in downstream phosphorylated ERK due to RAS inhibition when treated with B6 LNPs encapsulating K27 at high dose and B6 LNPs encapsulating K27-D30 at both low and high dose.